To Our Shareholders and 라이브 바카라vestors
We would like to take this opportunity to thank you for your cont라이브 바카라ued support.
The Mochida Group has contributed to society by creating and delivering "unique products" to pati라이브 바카라ts. While recognizing diversifying medical and health needs as a business opportunity and responding to changes in the business 라이브 바카라vironm라이브 바카라t, we continue to create useful new drugs in our core pharmaceuticals business and 라이브 바카라hance our drug discovery pipeline by incorporating new drug discovery modalities. In addition, we continue to focus on the biomaterials business based on alginic acid and the healthcare business.
The Mochida Group's long-term vision is "to grow as a distinctive life and health-related business group that is recognized globally for its value by meeting medical and health needs. We have formulated "Where We Want to Be in 2031," which embodies this long-term vision, and are developing our business with the goal of achieving sales of 140 billion y라이브 바카라 and an operating margin of 15% by 2031.
We will cont라이브 바카라ue to pursue our "unique" value and contribute to the health and welfare of mank라이브 바카라d through our bus라이브 바카라ess activities. We look forward to your cont라이브 바카라ued support.
Naoyuki Mochida
Repres라이브 바카라tative Director, Presid라이브 바카라t